Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective

Abstract

In view of the high risk of recurrent disease in stage III and IV ovarian cancer following primary first-line chemotherapy, a variety of maintenance and consolidation treatment strategies have been developed. These have included: radiation, intravenous or intraperitoneal chemotherapy, targeted therapies, and immunotherapy. Popular at this time is the use of Poly-adenosine ribose polymerase (PARP) inhibitors and bevacizumab as maintenance therapy. What effect these maintenance or consolidation therapies have on subsequent response to therapy, specifically platinum-based chemotherapy, is only beginning to be studied. In this manuscript, we review the impact of PARP inhibitors and bevacizumab as well as radiation and maintenance chemotherapy on subsequent response to treatment. Prior use of bevacizumab does not appear to adversely affect subsequent response to platinum-based chemotherapy or platinum-based chemotherapy with bevacizumab. Prior therapy with PARP inhibitors induces platinum resistance to subsequent platinum-based therapy and negates classic predictors of response such as platinum-free interval and breast cancer susceptibility gene (BRCA) mutational status.

Keywords

Maintenance / consolidation / PARP inhibitors / bevacizumab / radiation / chemotherapy

References

[1] Gadducci A,Conte PF.Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.Crit Rev Oncol Hematol2005;55:153-66

[2] Hirte H,Ferguson SE,Elit L.Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a systematic review.Crit Rev Oncol Hematol2021;162:103336

[3] Markman M.Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.J Clin Oncol1992;10:513-4

[4] Friedlander M,Tinker A.Gynecologic Cancer InterGroupClinical trials in recurrent ovarian cancer.Int J Gynecol Cancer2011;21:771-5

[5] Claussen C,Hanker L.Treatment of recurrent epithelial ovarian cancer.Geburtshilfe Frauenheilkd2020;80:1195-204 PMCID:PMC7714556

[6] Rottenberg S,Perego P.The rediscovery of platinum-based cancer therapy.Nat Rev Cancer2021;21:37-50

[7] Pennington KP,Harrell MI.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Clin Cancer Res2014;20:764-75 PMCID:PMC3944197

[8] Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma.Nature2011;474:609-15

[9] Tan DS,Thomas K.“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.J Clin Oncol2008;26:5530-6

[10] Lee EK.Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.Expert Opin Emerg Drugs2020;25:165-88

[11] Fong PC,Boss DS.Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.J Clin Oncol2010;28:2512-9

[12] Ang JE,Powell CB.Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.Clin Cancer Res2013;19:5485-93

[13] Cecere SC,Salutari V.Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome.Gynecol Oncol2020;156:38-44

[14] Baert T,Bommert M.828P Expected observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer.Annals of Oncology2020;31:S624

[15] Frenel J,Berton-rigaud D.813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: the SOLO2/ENGOT Ov-21 trial.Annals of Oncology2020;31:S615

[16] Rose PG,Chambers LM.PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.Anticancer Drugs2021;32:1086-92

[17] Johnson N,Yao W.Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.Proc Natl Acad Sci U S A2013;110:17041-6 PMCID:PMC3801063

[18] Matulonis UA,Gourley C.Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for postprogression poly (adenosine diphosphate ribose) polymerase inhibitor therapy.Cancer2016;122:1844-52

[19] Poveda A,Ledermann JA.Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.The Lancet Oncology2021;22:620-31

[20] Matulonis U,Oza A.Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer.Gynecologic Oncology2021;162:S24-5

[21] Bookman MA,Espirito JL,Fernandes AW.Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.Gynecol Oncol2017;146:58-63

[22] Jorge S,Norquist BM.Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.Gynecol Oncol Rep2019;29:113-7 PMCID:PMC6710556

[23] Rose PG,Chambers LM,Le P.The overtreatment and cost effectiveness of primary versus secondary maintenance therapy with poly-adenosine ribose phosphate inhibitors (PARPi) for epithelial ovarian cancer (EOC).Gynecol Obstet2021;11(9):570. PMCID:PMC8681231

[24] Burger RA,Bookman MA.Gynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancer.N Engl J Med2011;365:2473-83

[25] Oza AM,Pfisterer J.Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.The Lancet Oncology2015;16:928-36 PMCID:PMC4648090

[26] Tewari KS,Enserro D.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.J Clin Oncol2019;37:2317-28 PMCID:PMC6879307

[27] Coleman RL,Herzog TJ.Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.The Lancet Oncology2017;18:779-91 PMCID:PMC5715461

[28] Pignata S,Joly F.Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.The Lancet Oncology2021;22:267-76

[29] The ICON and AGO Collaborators.Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.The Lancet2003;361:2099-106

[30] Pujade-Lauraine E,Aavall-Lundqvist E.Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.J Clin Oncol2010;28:3323-9

[31] Kaye SB,Dańska-Bidzińska A.A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.Ann Oncol2013;24:145-52

[32] Pfisterer J,Vergote I.AGO-OVAR, NCIC CTG., EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.J Clin Oncol2006;24:4699-707

[33] Aghajanian C,Goff BA.OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol2012;30:2039-45 PMCID:PMC3646321

[34] Armstrong DK,Weil SC,Coleman RL.Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol2013;129:452-8

[35] Sehouli J,Reinthaller A.Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).Ann Oncol2016;27:2236-41

[36] Pfisterer J,Baumann K.Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.The Lancet Oncology2020;21:699-709

[37] Lawton F,Blackledge G.A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West midlands ovarian cancer group trial II.Clinical Oncology1990;2:4-9

[38] Lambert HE,Gregory WM.A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study.J Clin Oncol1993;11:440-8

[39] B; Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment.Int J Gynecol Cancer2003;13:278-86

[40] Louie KG,Kinsella TJ.Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.Cancer Res1985;45:2110-5. PMID: 3986765

[41] Varia MA,Bundy BN.Gynecologic Oncology GroupIntraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.J Clin Oncol2003;21:2849-55

[42] Markman M,Wilczynski S.Southwest Oncology Group, Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.J Clin Oncol2003;21:2460-5

[43] Pecorelli S,Gadducci A.After 6 Italian Cooperative GroupPhase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.J Clin Oncol2009;27:4642-8

[44] Copeland LJ,Burger RA. A randomized phase III trial of maintenance therapy comparing 12 monthly cycles of single agent paclitaxel or paclitaxel poliglumex (CT-2103, IND#70177)(PP), versus surveillance (S) in women with advanced ovarian/fallopian tube/peritoneal cancer (O/PC/FT) who achieved a complete clinical response (CCR) following first-line platinum-taxane therapy: An NRG Oncology study. Society Gynecologic Oncology Annual Meeting, National Harbor, Washington DC March 13, 2017.

[45] De Placido S,Di Vagno G.Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.J Clin Oncol2004;22:2635-42

[46] Pfisterer J,Reuss A.AGO-OVAR, GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.J Natl Cancer Inst2006;98:1036-45

[47] Bolis G,Tateo S.Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study.Int J Gynecol Cancer2006;16 Suppl 1:74-8